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Atherosclerosis is currently no longer considered merely
a cholesterol storage disease, but rather a complex process of
vascular inﬂammation (1,2). Indeed, various inﬂammatory
cells and, in particular, monocytes and macrophages play
a major role in the development, progression, and rupture of
atherosclerotic plaques (3). Atherosclerosis is initiated when
blood monocytes and T lymphocytes are attracted by che-
mokinesis to oxidized apo-B rich lipoproteins in the vessel
wall. Expression of vascular cell adhesion molecule-1 and E-
and P-selectin by the endothelium allows their adherence and
entry into the subendothelial space. Monocytes subsequentlySee page 909differentiate into mature macrophages, ingest the excessive
lipoproteins, and become the so-called cholesterol enriched
“foam cells.” The release of cytokines such as interleukins,
Tumor necrosis factor-alpha (TNF-a) and monocyte che-
motactic protein-1 by foam cells and lymphocytes, maintains
a state of chronic vascular inﬂammation, eliciting progression
of atherosclerosis. During this process even more monocytes
continue to enter the plaque and differentiate into macro-
phages, while smooth muscle cells and ﬁbroblasts undergo
proliferation. This leads to progressive enlargement of the
ﬁbro-atheromatous plaque. As atherosclerotic lesions evolve,
macrophage foam cells and smooth muscle cells can undergo
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Ongoing macrophage activation and inﬂammation leading to
necrosis of foam cells is believed to be a major factor in plaque
instability. Indeed, inﬂammatory cytokines and enzymes such
as interferon-g secreted by T lymphocytes inhibit production
of collagen by smooth muscle cells, while matrix metal-
loproteinases secreted by macrophages directly degrade and
thin the ﬁbrous cap. The release of procoagulant tissue factors
by T lymphocytes further increases the thrombogenic
potential of the plaque. These factors may lead to endothelial
rupture, resulting in exposition of tissue factor to platelets and
ﬁbrinogen with subsequent activation of the thrombotic
cascade, and acute intravascular thrombus formation. Such
acute atherothrombosis is the main mechanism underlying
acute coronary syndromes, stroke, and sudden death.
Experimental studies support the view that statins may
have unique pleiotropic effects, which may contribute to
their exclusive lipid-lowering independent protective clinical
efﬁcacy (4). By inhibiting the mevalonate pathway, statins
are thought to reduce protein isoprenylation, a process af-
fecting numerous vascular and myocardial signal pathways.
For instance, statins favorably affect endothelial nitric oxide
synthase (eNOS) gene expression and eNOS coupling in
the endothelium. This results in improved nitric oxide
bioavailability, improving endothelial dysfunction. Within
the atherosclerotic plaque itself, statins reduce reactive
oxygen species production by Nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase both in the endo-
thelium and the smooth muscle cells. Furthermore, through
inhibition of nuclear factor kappa-light-chain-enhancer of
activated B cell (NF-kB) activation by TNF-a, statins also
reduce vascular small cell monocytes interaction and decrease
pro-inﬂammatory cytokine production such as interleukins,
interferon gamma, and monocyte chemoattractant protein 1
expression. Finally, statins down-regulate matrix metal-
loproteinase activity. All these effects result in strong local
anti-inﬂammatory effects within the plaque, reduction of
inﬂammatory cell inﬁltration, and plaque stabilization. These
marked anti-inﬂammatory effects of statins can also be
demonstrated in vivo, and correlate with reduction of acute
events. A particular good example is the JUPITER (Justiﬁ-
cation for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin) study (5), where
rosuvastatin was shown to reduce event rates in patients with
normal low-density lipoprotein cholesterol but high high-
sensitivity C-reactive protein (CRP).
To detect vulnerable plaques in high-risk patients and to
monitor the effect of drug therapy such as statins on
vulnerable plaques in vivo, several noninvasive techniques
have been proposed (6). Among these, imaging of vascular
inﬂammation by 18F-ﬂuorodeoxyglucose positron emission
tomography (FDG-PET) is a particularly interesting ap-
proach (7). FDG is a glucose analog with a half-life of
110 min, which is taken up by facilitated glucose trans-
porters in competition with glucose into metabolically active
cells. It is then phosphorylated to 18FDG-6-phosphate by
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919hexokinase, but cannot be metabolized further and thus
accumulates within the cell. Clinical studies reported
increased FDG uptake in atherosclerotic plaques as
compared with normal vessels. Histologically, this FDG
uptake is conﬁned mainly to plaque macrophages, but not to
surrounding vascular smooth-muscle cells. Indeed macro-
phages comprise the vast majority of inﬂammatory cells in
human and experimental atherosclerotic plaques, and in the
anaerobic environment of the plaque, they preferentially rely
on glycolysis for adenosine triphosphate (ATP) production
and present increased expression of glucose transporters
receptors and hexokinase activity (7). FDG uptake in plaque
was shown to correlate signiﬁcantly with plaque macrophage
content, and is therefore thought to be a marker of plaque
inﬂammation. The current methodology for FDG PET
imaging of inﬂammation, involves acquisition of a 10- to
15-min static PET image 2 h after intravenous injection of
10 mCi FDG after overnight fasting. Quantiﬁcation of FDG
uptake in atherosclerotic plaque is performed by measuring
the standardized uptake value (SUV) of an artery of interest
and of the venous blood pool. Then the vascular target-
to-background ratio (TBR) is calculated by dividing the
vascular SUV by the venous blood pool SUV. This parameter
can be expressed either as maximum or mean TBR for
a vessel. This method has been shown to have high sensitivity
for detection of vascular inﬂammation, high inter- and intra-
reader reliability, and especially high interstudy reproduc-
ibility (8). Another advantage is the simplicity of the method,
which is nearly identical to standardized PET protocols
widely used for clinical oncology imaging.
Limitations of PET for vascular imaging (9) are, however,
its low spatial resolution of 3 to 4 mm requiring coregistration
with computed tomography or other techniques to localize
the underlying vessel. Moreover, given the small size of
atheromatous plaques, imaging with PET is subject to partial
volume errors, especially in small vessel such as coronary
arteries. A subsequent difﬁculty for imaging such coronary
vessels is the complex motion of the heart. FDG uptake is
inﬂuenced by dietary status and may be affected by diseases
such diabetes mellitus. Vascular signal can also be contami-
nated by spillover from neighboring muscular or ganglionic
structures. Finally, FDG-PET is not a speciﬁc tracer of
plaque inﬂammation, as mechanisms other than vascular
inﬂammation may also increase FDG uptake within the
atheroma (9). For instance, FDG uptake is dependent on
blood ﬂow and could be inﬂuenced by vasa-vasorium density
in the plaque. It could also increase if regional hypoxia
stimulates the glucose utilization rate of monocytes within the
plaque. Therefore, more speciﬁc nuclear imaging tracers for
vascular inﬂammation, which directly target macrophages or
metalloproteinases in the plaque are currently under devel-
opment (9).
Tawakol et al. (10), in this issue of the Journal, compared
the effect of low (10 mg) versus high (80 mg) dose ator-
vastatin on aortic or carotid arteries plaque inﬂammation in
67 patients by FDG-PET. Patients had prior coronary,carotid, or peripheral artery disease, diabetes type II, or
obesity, were-statin-naive or treated with low-dose statins,
and had to have at least 1 “hot” plaque in the aorta or carotid
on a baseline FDG-PET. The study evaluated the change of
TBR of the most diseased segment of the target vessel at 4
and 12 weeks after statin treatment versus baseline. It
demonstrated that both the low- and high-dose of statins
reduced FDG-TBR in the target vessel, but that the high-
statin dose was more effective in reducing plaque inﬂamma-
tion. Interestingly, but in accordance with other studies,
changes of FDG-TBRwere not correlated to changes in low-
density lipoprotein cholesterol or CRP. This is the ﬁrst
randomized multicenter trial demonstrating such effect of
statins on vascular inﬂammation by FDG-PET. It conﬁrmed
ﬁndings of an earlier single-center study evaluating simvas-
tatin (11). The main limitation of this study was that there
were missing data points, requiring the use of a sophisticated
multilinear model for allowing comparison of repeated
measurements with missing data. Also the study neither
measured other biomarkers of inﬂammation besides CRP nor
followed changes in plaque thickness or composition by
techniques such as ultrasound ormagnetic resonance imaging.
Besides demonstrating that atorvastatin has anti-
inﬂammatory effects in a dose-dependent response in ath-
erosclerotic patients, the study by Tawakol et al. (10) nicely
illustrates the usefulness of FDG-PET to study plaque
inﬂammation and its inﬂection by drug treatment in vivo.
Because of its high costs, it is unlikely that FDG-PET will
be widely used to identify high-risk plaques and to monitor
treatment response on targeted vessels in individual patients
clinically. However, as shown in the study in the present
issue PET is attractive to study anti-inﬂammatory effects of
various drugs in experimental trials. Accordingly, it has
been used to evaluate effects of cholesterol ester transfer
proteins inhibitors (12), p38 mitogen-activated protein
kinase inhibitors (13), niazin, ezetibmide, or PPAR-gamma
agonists (14) on plaque inﬂammation. Using PET to non-
invasively study drug effects on plaque inﬂammation in phase
II trials is clearly more attractive and cheaper than invasive
techniques such as intravascular ultrasound or optical coher-
ence tomography. Future prospective trials need, however, to
establish whether a decrease in plaque inﬂammation by FDG
PET by treatment, translates into a reduced risk of cardio-
vascular events.
The authors should be congratulated on performing this
interesting and well-designed trial, which nicely demon-
strates the usefulness of FDG-PET to study drug effect on
atherosclerotic plaques in vivo. Further studies employing
similar methodology will enhance our understanding on the
mode of action and efﬁcacy of new antiatherosclerosis drugs.Reprint requests and correspondence: Dr. Bernhard L. Gerber,
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